Increasing trend in fusidic acid resistance among MRSA isolates in the Netherlands, 2016-2023
Authors:
- Feline VelthuisFVFeline Velthuis
- Ilse M NautaINIlse M Nauta
- Wieke Altorf-Van der KuilWKWieke Altorf-Van der Kuil
- Daan W NotermansDNDaan W Notermans
- Romy D ZwittinkRZRomy D Zwittink
- Annelot F SchoffelenASAnnelot F Schoffelen
- Sabine C de GreeffSGSabine C de Greeff
- Infectious Diseases Surveillance Information System-Antimicrobial Resistance (ISIS-AR) Study GroupIGInfectious Diseases Surveillance Information System-Antimicrobial Resistance (ISIS-AR) Study Group
Preprint
Abstract
Synopsis: Objectives: Recently, several methicillin-resistant Staphylococcus aureus (MRSA) community outbreaks occurred in the Netherlands, including one caused by an impetigo-causing MRSA strain resistant to fusidic acid. Since fusidic acid and flucloxacillin are the main treatment options for impetigo, increasing resistance limits treatment possibilities. We examined trends in fusidic acid resistance levels among MRSA isolates in the Netherlands. Methods: Data on routine bacteriological cultures between 2016-2023 from 30 laboratories were extracted from the national surveillance system on antimicrobial resistance (ISIS-AR). Fusidic acid resistance rates per year were calculated both overall and per age group for all MRSA isolates, and more specific, for the subset of MRSA isolates from wound/pus/skin samples collected by general practitioners (WPS-GP-samples). Trends were determined using logistic regression and compared with trends among methicillin-susceptible S. aureus (MSSA) isolates. Results: We found an increasing trend in fusidic acid resistance among MRSA isolates from 15% in 2016 to 30% in 2023 (p<0.001) which differed significantly from the trend among MSSA isolates (p<0.001). An increase was also found in MRSA WPS-GP-samples, both among young children and the population of 13-64 years old, but not among elderly. The trends remained significant after exclusion of isolates associated with known fusidic acid-resistant MRSA outbreaks, both among MRSA isolates overall (OR = 1.10, 95% CI: 1.07-1.14, p<0.001) and among MRSA WPS-GP-samples (OR = 1.14, 1.07-1.21, p<0.001). Conclusions: In conclusion, an increasing trend in fusidic acid resistance was found among MRSA isolates. Since impaired treatment for impetigo might ease the spread of (fusidic acid-resistant) MRSA, extra vigilance is warranted.Keywords
This publication has 11 references indexed in Scilit:
- Molecular characterization of MRSA collected during national surveillance between 2008 and 2019 in the NetherlandsCommunications Medicine, 2023
- Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in BelgiumJournal of Antimicrobial Chemotherapy, 2023
- Treatment of Impetigo with Antiseptics—Replacing Antibiotics (TIARA) trial: a single blind randomised controlled trial in school health clinics within socioeconomically disadvantaged communities in New ZealandTrials, 2022
- Prevalence of nasal carriage of methicillin-resistant Staphylococcus aureus in patients at hospital admission in The Netherlands, 2010–2017: an observational studyClinical Microbiology and Infection, 2019
- National laboratory-based surveillance system for antimicrobial resistance: a successful tool to support the control of antimicrobial resistance in the NetherlandsEurosurveillance, 2017
- Spread of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) in general practice patients in the south of The NetherlandsJournal of Antimicrobial Chemotherapy, 2012
- Topical Retapamulin Ointment, 1%, versus Sodium Fusidate Ointment, 2%, for Impetigo: A Randomized, Observer-Blinded, Noninferiority StudyDermatology, 2007
- Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic useJournal of Hospital Infection, 2004
- A fusidic acid-resistant clone of Staphylococcus aureus associated with impetigo bullosa is spreading in NorwayJournal of Antimicrobial Chemotherapy, 2002
- Staphylococcus aureusInfectionsNew England Journal of Medicine, 1998